O'Shaughnessy Asset Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.8M | Buy |
245,899
+49,825
| +25% | +$2.14M | 0.05% | 336 |
|
|
2026
Q1 | $7.21M | Buy |
196,074
+2,017
| +1% | +$95.6K | 0.04% | 442 |
|
|
2025
Q4 | $9.87M | Sell |
194,057
-26,640
| -12% | -$1.36M | 0.05% | 359 |
|
|
2025
Q3 | $12.2M | Sell |
220,697
-60,896
| -22% | -$3.56M | 0.07% | 295 |
|
|
2025
Q2 | $19.4M | Buy |
281,593
+7,400
| +3% | +$503K | 0.13% | 182 |
|
|
2025
Q1 | $19M | Sell |
274,193
-15,368
| -5% | -$1.27M | 0.15% | 153 |
|
|
2024
Q4 | $24.9M | Sell |
289,561
-3,388
| -1% | -$366K | 0.21% | 97 |
|
|
2024
Q3 | $35.1M | Buy |
292,949
+40,484
| +16% | +$5.4M | 0.31% | 67 |
|
|
2024
Q2 | $36M | Buy |
252,465
+14,314
| +6% | +$1.9M | 0.37% | 51 |
|
|
2024
Q1 | $30.6M | Buy |
238,151
+26,830
| +13% | +$3.19M | 0.34% | 60 |
|
|
2023
Q4 | $21.9M | Buy |
211,321
+8,553
| +4% | +$846K | 0.29% | 84 |
|
|
2023
Q3 | $18.4M | Sell |
202,768
-5,378
| -3% | -$474K | 0.27% | 94 |
|
|
2023
Q2 | $16.8M | Buy |
208,146
+11,630
| +6% | +$950K | 0.25% | 106 |
|
|
2023
Q1 | $15.6M | Buy |
196,516
+14,118
| +8% | +$1M | 0.25% | 113 |
|
|
2022
Q4 | $12.3M | Buy |
182,398
+24,816
| +16% | +$1.45M | 0.2% | 136 |
|
|
2022
Q3 | $7.85M | Sell |
157,582
-1,752
| -1% | -$93.9K | 0.15% | 168 |
|
|
2022
Q2 | $8.88M | Buy |
159,334
+26,190
| +20% | +$1.45M | 0.16% | 153 |
|
|
2022
Q1 | $7.39M | Buy |
133,144
+35,318
| +36% | +$1.81M | 0.12% | 192 |
|
|
2021
Q4 | $5.48M | Buy |
97,826
+20,282
| +26% | +$1.1M | 0.1% | 215 |
|
|
2021
Q3 | $3.72M | Buy |
77,544
+28,796
| +59% | +$1.39M | 0.08% | 223 |
|
|
2021
Q2 | $2.04M | Sell |
48,748
-3,916
| -7% | -$152K | 0.04% | 310 |
|
|
2021
Q1 | $1.77M | Buy |
52,664
+16,076
| +44% | +$573K | 0.04% | 281 |
|
|
2020
Q4 | $1.28M | Buy |
36,588
+4,450
| +14% | +$154K | 0.03% | 293 |
|
|
2020
Q3 | $1.12M | Buy |
32,138
+6,026
| +23% | +$201K | 0.03% | 277 |
|
|
2020
Q2 | $855K | Buy |
26,112
+19,776
| +312% | +$631K | 0.03% | 301 |
|
|
2020
Q1 | $191K | Sell |
6,336
-1,582
| -20% | -$47.1K | 0.01% | 479 |
|
|
2019
Q4 | $229K | Buy |
7,918
+7,908
| +79,080% | +$219K | 0.01% | 586 |
|
|
2019
Q3 | $0 | Buy |
10
+6
| +150% | +$152 | ﹤0.01% | 1171 |
|
|
2019
Q2 | $0 | Buy |
+4
| New | +$99 | ﹤0.01% | 1148 |
|
|
2019
Q1 | – | Sell |
-13,470
| Closed | -$310K | – | 980 |
|
|
2018
Q4 | $310K | Sell |
13,470
-14,814
| -52% | -$329K | 0.01% | 421 |
|
|
2018
Q3 | $667K | Sell |
28,284
-14,724
| -34% | -$359K | 0.01% | 328 |
|
|
2018
Q2 | $992K | Sell |
43,008
-122
| -0.3% | -$2.9K | 0.02% | 252 |
|
|
2018
Q1 | $1.06M | Buy |
43,130
+8,950
| +26% | +$235K | 0.02% | 244 |
|
|
2017
Q4 | $917K | Buy |
34,180
+8,002
| +31% | +$204K | 0.02% | 286 |
|
|
2017
Q3 | $630K | Buy |
26,178
+16,766
| +178% | +$379K | 0.01% | 324 |
|
|
2017
Q2 | $202K | Buy |
+9,412
| New | +$190K | ﹤0.01% | 514 |
|
|
2016
Q2 | – | Sell |
-118
| Closed | -$3K | – | 982 |
|
|
2016
Q1 | $3K | Sell |
118
-140
| -54% | -$3.75K | ﹤0.01% | 859 |
|
|
2015
Q4 | $7K | Sell |
258
-92
| -26% | -$2.55K | ﹤0.01% | 768 |
|
|
2015
Q3 | $9K | Sell |
350
-168
| -32% | -$4.76K | ﹤0.01% | 716 |
|
|
2015
Q2 | $14K | Buy |
+518
| New | +$14.6K | ﹤0.01% | 708 |
|
|
2013
Q3 | – | Sell |
-860
| Closed | -$13K | – | 978 |
|
|
2013
Q2 | $13K | Buy |
+860
| New | +$14.3K | ﹤0.01% | 697 |
|
Other funds holding NVO
F
O'Shaughnessy Asset Management's NVO Position: Q2 2026 in Review
O'Shaughnessy Asset Management increased its Novo Nordisk (NVO) stake by 25% in Q2 2026, buying an estimated $2.14M and bringing the position to 245,899 shares worth $11.8M. The position accounts for 0.05% of the portfolio, ranked #336.
O'Shaughnessy Asset Management first reported a position in NVO in Q2 2013 and has held it in 41 quarters since. The position peaked at $36M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- O'Shaughnessy Asset Management held 245,899 shares of Novo Nordisk worth $11.8M as of Q2 2026.
- O'Shaughnessy Asset Management bought 49,825 Novo Nordisk shares in Q2 2026, an estimated $2.14M.
- Novo Nordisk made up 0.05% of O'Shaughnessy Asset Management's portfolio in Q2 2026, its #336 holding.
- O'Shaughnessy Asset Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 41 quarters since.
- O'Shaughnessy Asset Management's Novo Nordisk position peaked at $36M in Q2 2024.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.